TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases
In a small trial, the antibody-drug conjugate trastuzumab deruxtecan shrank brain metastases in almost three quarters of women with HER2-positive breast cancer, showing that a large antibody-based drug can work inside the brain.
Overview
Single-arm phase 2 trial of 15 patients with HER2-positive breast cancer and newly diagnosed or progressing brain metastases not needing immediate local therapy, treated with trastuzumab deruxtecan 5.4 mg/kg.
Intracranial response by RANO-BM criteria was 73.3 percent in the intention-to-treat population, with a median progression-free survival of 14 months and preserved quality of life. The larger DESTINY-Breast12 study later confirmed intracranial activity in a broader population.
- Intracranial objective response 73.3 percent.
- Median progression-free survival 14 months.
Trastuzumab deruxtecan is an option for active HER2-positive brain metastases, complementing tucatinib-based therapy, and challenges the assumption that antibody-drug conjugates cannot reach the brain.
- Very small single-centre study.
- Patients with lesions needing urgent local treatment were excluded.
Similar pages
not linked directly; found by shared links- TrialHER2CLIMB-05
Shares HER2-positive breast cancer with brain metastases, Trastuzumab.
- Key paperHER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases
Shares HER2-positive breast cancer with brain metastases, Trastuzumab.
- Key paperHER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib
Shares HER2-positive breast cancer with brain metastases, Trastuzumab.
- TrialA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Shares Trastuzumab deruxtecan, Trastuzumab.
- PairingTucatinib + trastuzumab + capecitabine for brain metastases
Shares HER2-positive breast cancer with brain metastases, Trastuzumab.
- TrialDESTINY-Breast12
Shares HER2-positive breast cancer with brain metastases, Trastuzumab deruxtecan.
- Key paperDESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer
Shares Trastuzumab deruxtecan, Trastuzumab.
- Key paperDESTINY-Lung02: two doses of trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer
Shares Trastuzumab deruxtecan, Trastuzumab.